Insurances & Business

Ranbaxy May Use M&A to Grow in Japan Generics Market

Investment | Sources: bnet.com

Similar/Related/News:

• The Long-Acting Opioid Market Was Valued At Over $3 Billion in 2007, and Is Due To Grow Until the Patent Expiry of Market Leader Oxycontin In 2011 (Business Wire)
DUBLIN, Ireland----Research and Markets has announced the addition of Commercial and Pipeline Insight: Opioids - Short acting and anti-abuse technolog...
• Nokia Plays Catch Up in Japan Cellphone Market
TOKYO (Reuters) - Nokia Corp <NOK1V.HE> will add public wireless LAN access to its handsets in Japan in a bid to keep pace with smaller Japa...
• Pfizer May Make Counter Bid For Ranbaxy: Report
MUMBAI (Reuters) - Pfizer Inc <PFE.N> may bid for Ranbaxy Laboratories Ltd <RANB.BO>, countering a $4.6 billion offer by Japan's Daiic...
• India’s Ranbaxy Falls Nearly 7 Percent After Lipitor Deal
NEW DELHI (Reuters) - Shares in Indian drugmaker Ranbaxy Laboratories Ltd <RANB.BO> fell nearly 7 percent on Thursday morning, after a paten...
• Daiichi to Pay Up to $4.6 Billion For Control of Ranbaxy
TOKYO/NEW DELHI (Reuters) - Japanese drug maker Daiichi Sankyo Co Ltd <4568.T> moved to take majority control of India's biggest drug maker ...
• Japan Will Not Fall Into Recession: BOJ Report
TOKYO (Reuters) - Japan's economy will not fall into recession despite a likely slowdown in the first half of this fiscal year, partly because of ...
• Morgan Stanley Strengthens Japan Private Equity
TOKYO (Reuters) - Investment bank Morgan Stanley <MS.N> said it had appointed Yoshihiko Shigenari head of its private equity unit in Japan a...
• JAL to Sharply Beat Its 07/08 Profit Forecast Media
TOKYO (Reuters) - Japan Airlines Corp <9205.T> said on Friday it had roughly doubled its 2007/08 profit estimates to above market expectatio...